Proliferative and Survival Effects of PUMA Promote Angiogenesis  by Zhang, Fan et al.
Cell Reports
ArticleProliferative and Survival Effects
of PUMA Promote Angiogenesis
Fan Zhang,1 Yang Li,1 Zhongshu Tang,1,2 Anil Kumar,1 Chunsik Lee,1 Liping Zhang,3 Chaoyong Zhu,4
Anne Klotzsche-von Ameln,5 BinWang,6 Zhiqin Gao,7 Shizhuang Zhang,8 Harald F. Langer,9 Xu Hou,10 Lasse Jensen,11,12
Wenxin Ma,1 Wai Wong,1 Triantafyllos Chavakis,5 Yizhi Liu,2 Yihai Cao,11,12 and Xuri Li1,2,*
1National Eye Institute, National Institutes of Health, Rockville, MD 20852, USA
2State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, P.R. China
3National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD 20892, USA
4School of Public Health, NanTong University, 9 Seyuan Road, Nantong 226019, P.R. China
5Division of Vascular Inflammation, Diabetes and Kidney, Department of Medicine, and Institute of Physiology, University Dresden,
Dresden 0351 463-0, Germany
6Medical Imaging Institute, Shandong Province Characteristical Key Subject, Medical Imaging and Nuclear Medicine, Binzhou Medical
University, Yantai, 264003 P.R. China
7Department of Cell Biology
8Department of Radiology, Medical Imaging Centre of the Affiliated Hospital
Weifang Medical University, Weifang, 261053, P.R. China
9Department of Cardiovascular Medicine, University of Tu¨bingen, Tu¨bingen 72074, Germany
10Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi‘an, Shaanxi 710032,
China
11Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden
12Department of Medicine and Health Sciences, Linko¨ping University, 581 83 Linko¨ping, Sweden
*Correspondence: xurili18@gmail.com
http://dx.doi.org/10.1016/j.celrep.2012.09.023SUMMARY
The p53 upregulated modulator of apoptosis (PUMA)
is known as an essential apoptosis inducer. Here, we
report the seemingly paradoxical finding that PUMA
is a proangiogenic factor critically required for the
proliferation and survival of vascular and microglia
cells. Strikingly, Puma deficiency by genetic deletion
or small hairpin RNA knockdown inhibited develop-
mental and pathological angiogenesis and reduced
microglia numbers in vivo, whereas Puma gene
delivery increased angiogenesis and cell survival.
Mechanistically, we revealed that PUMA plays a
critical role in regulating autophagy by modulating
Erk activation and intracellular calcium level. Our
findings revealed an unexpected function of PUMA
in promoting angiogenesis and warrant more careful
investigations into the therapeutic potential of PUMA
in treating cancer and degenerative diseases.INTRODUCTION
The p53 upregulated modulator of apoptosis (PUMA) is a
member of the BH3-only protein family and has been known as
an essential apoptosis inducer for many years (Chipuk et al.,
2005; Vousden, 2005; Yu and Zhang, 2003). The apoptosis-
inducing activity of PUMA has been shown in different cell
types, such as mouse embryonic fibroblasts, developing neu-
rons, lymphocytes, tumor cells, and intestinal progenitor/stem1272 Cell Reports 2, 1272–1285, November 29, 2012 ª2012 The Autcells (Michalak et al., 2010; Villunger et al., 2003). Due to its
potent apoptotic activity, PUMA has received considerable
research interest and has been considered as an important ther-
apeutic candidate gene for the prevention and treatment of
cancer and degenerative diseases (Ito et al., 2005; Yu, 2009).
Despite many years of intensive studies on PUMA, out-
standing questions remain. Numerous studies have shown that
enhanced PUMA expression is not always linked to apoptosis.
Interaction of human umbilical vein endothelial cells (HUVECs)
with monocytes increased PUMA protein level in the former (Ga-
wad et al., 2009), yet the elevated PUMA protein level did not
result in apoptosis of the cells (Gawad et al., 2009). In brain
ischemia, PUMA expression was markedly upregulated (Kuroki
et al., 2009). However, apoptosis was not increased, and the
brain stroke volume was unchanged in the Puma-deficient
mice (Kuroki et al., 2009). The biological consequences of such
increased PUMA expression remain thus far unclear, indicating
potentially unknown functions of PUMA other than induction of
apoptosis. In addition, studies have shown that the proapoptotic
action of PUMA may be cell specific. For example, although
Puma deficiency reduced apoptosis in intestinal progenitor/
stem cells, it did not affect apoptosis of endothelial cells (Qiu
et al., 2008). Moreover, PUMA is highly expressed in vascular
andmicroglia cells (Tables S1 and S2), yet it has not been shown
to induce apoptosis in these cells thus far. Instead, little is known
about the function of PUMA in vascular and microglia cells. Of
note, PUMA was recently reported to be required for tumor
development, whereas Noxa, another proapoptotic gene of the
BH3-only protein family, inhibited tumorigenesis (Labi et al.,
2010; Michalak et al., 2010; Qiu et al., 2011), demonstrating
a distinct proliferative effect of PUMA compared with the otherhors
proapoptotic genes. Together, accumulating data have indi-
cated a potential unknown function of PUMA not related to
apoptosis, at least in certain types of cells.
Microglia are resident macrophages of the CNS. Although the
immune function of microglia has been widely studied, their role
in angiogenesis is not well understood. Some studies reported
an angiogenic effect of microglia (Checchin et al., 2006; Liu
et al., 2005; Yamaguchi et al., 2011), whereas others reported
an antiangiogenic effect (Stefater Iii et al., 2011). Interestingly,
in the developing mouse retina, the microglia density increases
during the first postnatal week and decreases gradually (Santos
et al., 2008). The appearance of retinal microglia precedes and
overlaps with the formation of retinal blood vessels, indicating
a potential role of microglia in retinal angiogenesis. Further
studies are needed to better understand the function of microglia
in blood vessel growth.
In the present study, we investigated the effect of PUMA on
vascular and microglia cells. We provide evidence that PUMA
is an angiogenic factor critically required for the proliferation
and survival of vascular and microglia cells by modulating auto-
phagy. At the molecular level, we revealed that PUMA plays
a crucial role in regulating Erk activation and intracellular
calcium level. Our data revealed an unexpected function of
PUMA as an angiogenic factor by promoting survival and prolif-
eration, which contradicts its known role as an essential
apoptosis inducer.
RESULTS
PUMA Is Expressed by Retinal Microglia and Blood
Vessels
Although PUMA has been intensively studied for many years, its
role in the retina remains unexplored. Therefore, we investigated
the retinal expression pattern of PUMA. Real-time PCR dis-
played a postnatal increase in PUMA expression and a subse-
quent decrease after postnatal day 18 (P18) (Figure 1A). This
was confirmed at the protein level by western blot (Figure 1B).
Immunofluorescence staining detected abundant PUMA ex-
pression in blood vessels (Figure 1C) and CD11b+ microglia in
the developing mouse retinae (Figure 1D). PUMA expression
was also identified in primary retinal microglia isolated from
neonatal mice (Figure 1D). Notably, PUMA expression levels in
the developing mouse retinae coincided with the time window
of retinal blood vessel development, which occurs mainly within
the first postnatal 2 weeks. Moreover, the retinal PUMA expres-
sion levels paralleled the timewindow of the emergence of retinal
microglia cells, the number of which increases in the retina
during the first postnatal week and decreases gradually there-
after (Santos et al., 2008). In neonatal mice, the retinal microglia
cells are mainly present in the retinal ganglion cell (RGC) layer
and the inner nuclear layer (INL) (Santos et al., 2008), where
PUMA expression is abundant (Figure 1C). Thus, even though
the changes in retinal PUMA expression (Figures 1A and 1B)
may reflect changes in PUMA expression in retinal neurons,
the spatiotemporal correlation of the expression level and distri-
bution of PUMA with retinal blood vessel formation and the
appearance and location of retinal microglia cells suggest a
potential effect of PUMA on retinal microglia and blood vessels.Cell RePuma Deficiency Decreased Microglia and Blood Vessel
Density in the Retina
We subsequently investigated the role of PUMA in the retina
using Puma-deficient mice. Because PUMA is known as an
essential apoptosis inducer (Chipuk et al., 2005; Vousden,
2005; Yu and Zhang, 2003), we hypothesized that Puma defi-
ciency might lead to decrease apoptosis in the retina. Surpris-
ingly, we found a marked decrease of retinal microglia numbers
in the Puma-deficient mice (Figures 1E, 1F, S1A, and S1B).
Importantly, loss of one Puma allele, i.e., loss of half of its normal
expression level (Figure S1C), decreased retinal microglia
density at different time points (Figures S1D–S1F). Puma defi-
ciency also decreased retinal blood vessel branch points, vessel
areas, and diameter (Figures 1F, S1G, and S1H).
To further verify these findings, we intercrossed Puma-defi-
cient mice with Cx3cr1GFP/+ transgenic mice, in which microglia
are GFP labeled (GFP expression under the control of a Cx3cr1
promoter) with a normal density and morphology (Davalos
et al., 2005). We found that the retinal microglia and blood
vessel densities decreased in the Puma-deficient Cx3cr1GFP/+
mice at different time points (Figures 1G and S1I). The
decreased retinal blood vessel branch points, vessel areas,
and diameters were also observed in the retinae of 6-month-
old Puma-deficient mice (Figure 1H). We next investigated mi-
croglia and blood vessel density in the brains of Puma-deficient
mice to verify whether the effect of PUMA was retina specific.
We found reduced microglia (Figure S1J) and blood vessel
density in the brains of Puma-deficient mice as well
(Figure S1K).
Puma Knockdown by Small Hairpin RNA Reduced
Microglia and Blood Vessel Density in the Retina
The observation of decreased microglia and blood vessel den-
sity in the Puma-deficient retina and brain was unexpected,
given the known apoptotic activity of PUMA (Chipuk et al.,
2005; Vousden, 2005; Yu and Zhang, 2003). To substantiate
our findings, we performed a loss-of-function assay using
Puma small hairpin RNA (shRNA). Intravitreal injection of mouse
Puma shRNA at P1 decreased PUMA expression level by about
60% in the retinae (Figures S2A and S2B) and decreased retinal
microglia number, blood vessel branch points, and vessel areas
at P6 (Figure 2A).
Puma Deficiency Did Not Affect Retinal Astrocytes or
Decrease Retinal Thickness
Because retinal astrocytes are known to contribute to retinal
angiogenesis, we investigatedwhetherPumadeficiency affected
the retinal astrocyte network and found no significant difference
in astrocyte area or morphology between wild-type and Puma-
deficient retinae (Figure S2C). We further assessed vascular
endothelial growth factor (VEGF) expression levels in Puma-defi-
cient and wild-type retinal astrocytes and found a slightly higher
VEGF protein level in Puma-deficient astrocytes (Figure S2D).
Similarly, real-time PCR and western blot showed that VEGF
expression level was somewhat higher in the Puma-deficient
retinae (Figures S2E and S2F). Thus, the vascular defects in the
Puma-deficient retinae were unlikely due to a potential astrocyte
or VEGF defect.ports 2, 1272–1285, November 29, 2012 ª2012 The Authors 1273
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Figure 2. Puma Knockdown by shRNA Re-
duced Microglia Number and Blood Vessel
Density, and PUMA Is Required for the
Expression of Important Angiogenic Genes
(A) Immunofluorescence staining showed that in-
travitreal injection of mouse Puma shRNA at P1
reduced retinal microglia (Ib1+, green) number,
blood vessel (IB4+, red) branch points, and vessel
areas at P6 (n = 8, p < 0.01 or 0.05).
(B) Depletion of retinal microglia by intravitreal and
intraperitoneal injection of clodronate liposome
decreased retinal blood vessel (IB4+, white)
branch points and vessel areas (n = 8, p < 0.01).
(C) Real-time PCR detected the expression of
numerous important angiogenic genes in the iso-
lated primary retinal microglia.
(D and E) Real-time PCR showed that Puma defi-
ciency by shRNA knockdown (D) or genetic dele-
tion (E) inhibited the expression of numerous
angiogenic genes in isolated primary retinal mi-
croglia in vitro and in the retina in vivo.
(F) Real-time PCR showed that PUMA over-
expression by gene delivery upregulated the ex-
pression of many angiogenic genes in microglia
cells.
(G–I) Western blot showed that Puma deficiency
by genetic deletion reduced the protein levels of
several important angiogenic factors in mouse
retinae, such as FGF2, IL6, and CCL2.
Scale bars represent 50 mm (A) or 200 mm (B). Data
are represented as mean ± SEM; *p < 0.05, **p <
0.01. See also Figure S2 and Table S3.Loss of retinal neurons can subsequently lead to loss of retinal
blood vessels (Zheng et al., 2007). We next investigated whether
Puma deficiency resulted in retinal neuronal loss, which could in
turn explain the angiogenesis defect. We measured the thick-
ness of the retinal layers where the retinal blood vessels exist,
i.e., the RGC layer, the inner plexiform layer (IPL), and the INL.
We found no significant difference in the thickness of the retinal
layers before birth at E18 (Figure S2G). After birth, in Puma-defi-
cient mice, the thicknesses of the RGC, IPL, INL, and the wholeFigure 1. Puma Deficiency Decreased Microglia Number and Blood Vessel Density in the Retin
(A) Real-time PCR showed that PUMA expression level in the developing mouse retinae increased after birth
(B) Western blot showed at a protein level that PUMA expression in the developing mouse retinae increased
(C) Immunofluorescence staining detected PUMA expression (green) in the retinal blood vessels (red), RGC
layer (ONL).
(D) Immunofluorescence staining detected PUMA expression (red) in CD11b+ (green) resident and isolated
retinae. DAPI, diamidino-2-phenylindole fluorescent staining of nuclei.
(E) Immunofluorescence staining showed decreased Iba1+ (green) retina microglia density at embryonic day
(F) Immunofluorescence staining showed decreased Iba1+ (green) retina microglia density, blood vessel (IB4+,
8, p < 0.001 or 0.01).
(G) In the Puma-deficient Cx3cr1GFP/+ mice with GFP-labeled microglia, retinal microglia (green) density, bloo
decreased (n = 10, p < 0.001 or 0.01).
(H) In 6-month-old Puma-deficient mice, retinal blood vessel (IB4+, green) branch points, vessel areas, and di
Scale bars represent 50 mm (C, upper; D, F, G); 20 mm (C, lower); 200 mm (E); or 100 mm (H). Data are represente
Figure S1 and Tables S1, S2, and S3.
Cell Reports 2, 1272–1285, Noretina were increased (Figures S2H–S2J).
There was no significant difference in the
thickness of the other retinal layers inPuma-deficient mice (data not shown). Moreover, PUMAoverex-
pression in the retinal ganglion cell line (RGC5) markedly induced
apoptosis (Figures S2K–S2M), consistent with the in vivo obser-
vation that Puma deficiency increased thickness of the retinal
ganglion cell layer (Figures S2H–S2J). In summary, Puma defi-
ciency did not lead to retinal neuronal loss.
To address whether the effect of PUMA on retinal microglia
and blood vessels was a common event of the BH3-only protein
family genes, we utilized Noxa-deficient mice. Like PUMA, Noxaa
and decreased after postnatal day 18 (P18).
after birth and decreased after P18.
layer, INL, and the outer part of the outer nuclear
primary retinal microglia in the developing mouse
18 (E18) and P3 (n = 7 or 8, p < 0.001 or 0.01).
red) branch points, and vessel areas at P6 (n = 7 or
d vessel (IB4+, red) branch points, and areas were
ameters were decreased (n = 7, p < 0.001 or 0.01).
d asmean ±SEM; **p < 0.01, ***p < 0.001. See also
vember 29, 2012 ª2012 The Authors 1275
is also a p53-upregulated proapoptotic gene of the BH3-only
protein family. However, no significant microglia or vascular
defects were observed in Noxa-deficient mice (Figure S2N),
demonstrating a functional uniqueness of PUMA.
Retina Microglia Cells Are Required for Retinal
Angiogenesis
Microglia cells are present in the mouse retina as early as at
embryonic day 11.5 (E11.5) (Santos et al., 2008), before the
mouse retinal vasculature starts to develop at postnatal day 1
(P1). Because the observed retinal microglia cell defect pre-
cedes the retinal blood vessel defect in the Puma-deficient
mice, we hypothesized that microglia loss in the Puma-deficient
retinae might relate to the vascular defect. To test this, we
depleted the mouse retinal microglia at P1 (a time point when
retinal angiogenesis just begins) by intravitreal and intraperito-
neal injection of clodronate liposomes, which reduced retinal mi-
croglia numbers by about 50% (Figure 2B). Microglia depletion
decreased retinal blood vessel branch points and vessel areas
(Figure 2B), demonstrating that retinal microglia are required
for retinal angiogenesis. Consistently, real-time PCR showed
that isolated primary retinal microglia expressed numerous
angiogenic factors (Figure 2C). Importantly, Puma deficiency
by genetic deletion or shRNA knockdown markedly decreased
the expression of many proangiogenic genes in primary retinal
microglia in vitro and in the retina in vivo (Figures 2D and 2E).
Vice versa, overexpression of PUMA upregulated the expression
of some angiogenic genes (Figure 2F). Western blot confirmed
the downregulation of some important angiogenic factors,
such as fibroblast growth factor 2 (FGF2), IL6, and CCL2, in
Puma-deficient retinae (Figures 2G–2I). Together, these data
demonstrate that retinal microglia contribute to retinal angiogen-
esis by producing important angiogenic factors.
Impaired Angiogenic Response in Puma-Deficient
Aortic Ring and Cornea
We subsequently used an aortic ring and a cornea pocket
assay to investigate whether Puma deficiency affected angio-
genesis in other tissues. In the aortic ring assay,Puma deficiency
nearly completely abolished VEGF- and FGF2-induced angio-
genesis (Figures 3A and 3B). Immunofluorescence staining
revealed less CD11b+ cells in Puma-deficient aortic rings (Fig-
ure 3C). In the cornea pocket assay, Puma deficiency impaired
VEGF-induced angiogenesis (Figures 3D and S3A–S3C). Immu-
nofluorescence staining revealed fewer CD11b+ cells in Puma-
deficient corneas (Figure 3E). Thus, Puma deficiency impaired
angiogenesis in other tissues than the retina.
Puma Deficiency Inhibited Choroidal
Neovascularization
We next tested whether Puma deficiency affected choroidal
neovascularization (CNV) using Puma-deficient mice and Puma
shRNA in a laser-induced CNV model. Puma deficiency de-
creasedCNVareabymore than50%(Figure 3F).Moreover, intra-
vitreous injection of Puma shRNA, which decreased PUMA
expression by about 60% in the retinae and choroids (Fig-
ure S3D), inhibited CNV formation (Figure 3G) and decreased
the number of CNV-associated Iba1+ microglia (Figure 3G). In-1276 Cell Reports 2, 1272–1285, November 29, 2012 ª2012 The Autdeed, real-time PCRdisplayed decreased expression of different
microglia markers, including Iba1 (Figure 3H), CD11b, and CD68
(Figure S3E) in the Puma shRNA-treated choroids and retinae.
Consistent with the reduced CNV areas by Puma shRNA treat-
ment, the expression of many important angiogenic genesmark-
edly decreased in the Puma shRNA-treated choroids and retinae
(Figure S3F).
PUMA Is Required for Vascular and Microglia Cell
Proliferation and Survival
To investigate the cellular mechanisms underlying the effect
of PUMA, we explored whether PUMA affected vascular and
microglia cell proliferation and survival. In cultured primary retinal
microglia, brain endothelial cells (ECs), and aortic artery smooth
muscle cells (SMCs), Puma deficiency decreased cell prolifera-
tion and survival under different conditions (Figures 4A–4C).
Consistently, Puma knockdown by shRNA, which decreased
PUMA expression in primary microglia by about 40% (Figures
S4A and S4B), decreased viability of primary retinal and brain
microglia (Figures 4D and S4C). On the other hand, PUMA over-
expression increased survival of primary retinal microglia cells
(Figures 4E, 4F, and S4D) and proliferation of rat retinal vascular
endothelial cells (TR-iBRB) and HUVECs (Figures 4G, 4H, S4E,
and S4F). PUMA overexpression did not induce, but instead
inhibited, apoptosis in the rat retinal vascular endothelial cells
(TR-iBRB, Figures S4G and S4H).
We next engaged several more direct methods than the MTT
assay to further verify the proliferative and survival effect of
PUMA, such as the BrdU assay, the trypan blue exclusion assay,
and the LIVE/DEAD viability/cytotoxicity assay. Using the BrdU
assay, we found that overexpression of PUMA increased cell
proliferation in the primary microglia cells (Figures 4I and S4I),
TR-iBRB, and HUVECs at different time points (Figures 4J, 4K,
S4E, and S4F), whereas PUMA deficiency by shRNA knockdown
inhibited proliferation of primary microglia (Figures 4L and S4J).
To investigate the survival effect of PUMA, we treated the cells
with mitomycin C to suppress cell proliferation, and performed
a trypan blue exclusion assay and a LIVE/DEAD viability/cytotox-
icity assay. Using these twomethods, we found that overexpres-
sion of PUMA increased survival of primary microglia (Figures
4M and S4I), whereas Puma shRNA treatment decreased their
survival (Figures 4N, 4O, and S4J). Thus, apart from the MTT
assay, several additional assays demonstrated a proliferative
and survival effect of PUMA on microglia and vascular cells.
Furthermore, Puma deficiency impaired retinal microglia migra-
tion induced by ATP, CCL2, and CCL3 (Figure 5A).
Puma Deficiency Impairs Erk Activation and M-CSFR
Expression
We subsequently investigated the molecular mechanisms un-
derlying the actions of PUMA. Puma deficiency markedly
attenuated Erk activation under different conditions in primary
brain vascular endothelial (Figure 5B) and retinal microglia cells
(Figure 5C). Consistently, Puma knockdown by shRNA inhibited
Erk activation in primary microglia (Figures 5D, S4A, and S4B). In
addition, the expression level of macrophage colony stimulating
factor receptor (M-CSFR), a factor mainly expressed by micro-
glia/macrophages and critical for angiogenesis (Kubota et al.,hors
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Figure 3. Impaired Angiogenesis in Puma-Deficient Aorta, Cornea and Choroidal Neovascularization
(A and B) Puma deficiency by genetic deletion nearly completely abolished VEGF- and FGF2-induced angiogenesis in an aortic ring assay (n = 5–7, p < 0.001).
(C) Immunofluorescence staining showed less CD11b+ cells in the Puma-deficient aortic rings (n = 4, p < 0.001).
(D) Puma deficiency by genetic deletion impaired VEGF-induced angiogenesis in a cornea pocket assay (n = 8, p < 0.05).
(E) Immunofluorescence staining showed fewer CD11b+ cells in the Puma-deficient corneas (n = 8 or 6, p < 0.05).
(F) IB4 immunofluorescence staining (red) showed that Puma deficiency decreased CNV area by more than 50% in a laser-induced CNV model (n = 8,
p < 0.001).
(G) IB4 immunofluorescence staining (red) showed that Puma shRNA treatment inhibited CNV formation (n = 9, p < 0.05) and decreased the number of Iba1+CNV-
associated microglia (n = 8, p < 0.05).
(H) Real-time PCR revealed decreased expression of the microglia marker Iba1 in Puma shRNA-treated choroids (n = 6, p < 0.001).
Scale bars represent 200 mm (A, B), 100 mm (C, E–G), or 500 mm (D). Data are represented as mean ± SEM; *p < 0.05, ***p < 0.001. See also Figure S3 and
Table S3.2009), considerably decreased in Puma-deficient microglia and
retinae (Figures 5E and 5F). This observation is consistent with
the finding of less microglia in Puma-deficient retinae. Moreover,
the expression levels of M-CSFR in cultured primary microglia
in vitro and inmouse retinae in vivo decreased afterPuma shRNA
treatment (Figures 5G, 5H, S2A, and S2B). Importantly, Puma
gene delivery by in vivo transfection of PUMA-expressing DNA
plasmids into P1 Puma-deficient mouse retinae increased retinal
microglia numbers (Figures 5I, 5J, and S5A–S5C), retinal
vascular branch points and vascular area (Figures 5K and 5L),
and restored M-CSFR expression and Erk activation at P6
(Figure 5M). Thus, PUMA is critically required for Erk activation
and M-CSFR expression, both of which are important for angio-
genesis and microglia proliferation, survival, and migration (LivaCell Reet al., 1999; Otero et al., 2009; Reddy et al., 2009; Sasaki et al.,
2000).
PUMA Is Required for Vascular and Microglia Cell
Autophagy
Our finding that PUMA is required for vascular and microglia cell
proliferation and survival was unexpected, as it contradicted
the common belief that PUMA is an essential apoptosis inducer.
To understand this paradox, we investigated whether PUMA
affected autophagy, a critical regulatory process of cell survival
and proliferation, under conditions of metabolic stress (Rabino-
witz and White, 2010). The intensity of the LC3II band (16 kDa)
was used as a marker for autophagy using western blots.
Puma deficiency markedly impaired autophagy under variousports 2, 1272–1285, November 29, 2012 ª2012 The Authors 1277
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(A) Puma deficiency markedly decreased retinal
microglia migration induced by ATP, CCL2 and
CCL3 (n = 7–10, p < 0.001).
(B and C) Puma deficiency markedly attenuated
Erk activation under different conditions in primary
brain vascular endothelial (B) and retinal microglia
cells (C).
(D) Puma knockdown by shRNA inhibited Erk
activation in primary microglia cells.
(E and F) The expression level of macrophage
colony stimulating factor receptor (M-CSFR)
markedly decreased in the Puma-deficient (KO)
microglia and retinae (n = 6).
(G and H) Puma knockdown by shRNA decreased
M-CSFR expression in cultured primary microglia
in vitro and in mouse retina in vivo.
(I–L) Puma gene delivery by in vivo transfection of
a PUMA-expressing DNA plasmid (PUMA pls) into
P1Puma-deficientmouse retinae increased retinal
microglia number (I, J n = 6, p < 0.05), retinal blood
vessel branch points (K, n = 7 or 8, p < 0.05) and
vascular areas (L, n = 7 or 8, p < 0.05).
(M) Puma gene delivery by in vivo transfection
of a PUMA-expressing DNA plasmid (PUMA pls)
into P1 Puma-deficient mouse retinae increased
M-CSFR expression and Erk activation at P6.
Scale bars in A and H represent 50 mm. Data are
represented as mean ± SEM; *p < 0.05. See also
Figure S5.conditions in primary retinal microglia (Figure 6A), brain vascular
ECs (Figure 6B) and aortic artery SMCs (Figure 6C), as
demonstrated by the disappearance or reduced intensity of theFigure 4. PUMA Is Required for Microglia and Vascular Cell Proliferation, Survival, and Migrati
(A–C) MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) cell proliferation/survival assay sh
eration and survival in cultured primary retinal microglia (A) and brain endothelial cells (B) in hypoxia and aortic
p < 0.001 or 0.01). In (B) and (C), fold change is presented using values of day 0 as 1.
(D) Puma knockdown by shRNA decreased the viability of Iba1+ primary retinal microglia cells in hypoxia
fluorescent staining of nuclei.
(E and F) Puma gene delivery increased the survival of primary retinal microglia cells in normoxia (E, n = 6, p <
p < 0.001).
(G andH)Puma gene delivery increased proliferation/survival of rat retinal vascular endothelial cells (G, TR-iBR
(I–K) BrdU assay showed that overexpression of PUMA increased cell proliferation of primary microglia cells (
cells (TR-iBRB, J), and HUVECs (K, n = 3, p < 0.05 or 0.01).
(L) BrdU assay showed that PUMA deficiency by shRNA knockdown inhibited the proliferation of primary m
(M) Trypan blue exclusion assay showed that overexpression of PUMA increased the survival of primarymicrog
mitomycin C to suppress cell proliferation (n = 3, p < 0.05).
(N and O) A LIVE/DEAD viability/cytotoxicity assay that selectively labels viable cell bodies with the calcein AM
EthD-1 red fluorescence showed that PUMA deficiency by shRNA knockdown decreased the survival of prim
and treated with mitomycin C to suppress cell proliferation (n = 3, p < 0.001).
Scale bars in (D) and (O) represent 50 mm. Data are represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p
Cell Reports 2, 1272–1285, No16 kDa LC3II band (Figures 6A–6C).
Consistently, Puma shRNA treatment
markedly inhibited autophagy in the
RAW264.7 macrophage cells (Figures
6D and S6A), whereas overexpression
of PUMA increased autophagy in
RAW264.7 cells and primary retinal mi-
croglia (Figures 6E, 6F, S6B, and S6C).Moreover, immunofluorescence staining showed that overex-
pression of PUMA in primary retinal microglia increased
autophagy as demonstrated by the increased LC3+ dotson
owed that Puma deficiency decreased cell prolif-
artery smooth muscle cells in normoxia (C) (n = 4,
(n = 8, p < 0.01). DAPI: diamidino-2-phenylindole
0.01) and with a greater effect in hypoxia (F, n = 6,
B, n = 4, p < 0.001) and HUVECs (H, n = 4, p < 0.05).
I, n = 3, p < 0.05 or 0.01), retina-derived endothelial
icroglia cells (n = 3, p < 0.05).
lia cultured in serum-freemedium and treatedwith
green fluorescence and dead cell nucleus with the
ary microglia cells cultured in serum-free medium
< 0.001. See also Figure S4.
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Figure 6. PUMA Is Required for Microglia and Vascular Cell Autophagy
(A–C) Western blot showed that Puma deficiency (KO) markedly impaired autophagy under different conditions in primary retinal microglia (A), brain vascular
endothelial cells (B), and aortic artery smooth muscle cells (SMC, C), as demonstrated by the disappearance or decreased intensity of the 16 kDa LC3II band.
(D) Western blot showed that Puma knockdown by shRNAmarkedly inhibited autophagy in the RAW264.7 macrophage cells as demonstrated by the decreased
intensity of the 16 kDa LC3II band.
(E and F)Western blot showed that PUMA overexpression increased autophagy in both RAW264.7macrophage cells and primary retinal microglia under different
conditions as demonstrated by the increased intensity of the 16 kDa LC3II band.
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(Figures 6G [arrows] and S6C), whereas Puma deficiency
decreased autophagy in primary brain ECs (less LC3+ dots) (Fig-
ure 6H, arrows).
PUMA-Induced Autophagy Requires Erk Activation
BecausePuma deficiency attenuated Erk activation (Figures 5B–
5D), we hypothesized that PUMA-induced autophagy might
require Erk activation and tested this hypothesis. Treatment
with an Erk1/2 inhibitor U0126 inhibited Erk activation and
PUMA-induced autophagy in primary microglia (Figures 6I and
S6C) and TR-iBRB (Figures 6J and S4E). Consistently, immuno-
fluorescence staining showed that while PUMA overexpression
induced autophagy in the TR-iBRB cells (Figure 6K, middle
panel, arrows showing the increased LC3+ dots), U0126 treat-
ment abolished PUMA-induced autophagy (Figure 6K, right
panel, decreased LC3+ dots). Moreover, western blot showed
that U0126 treatment inhibited Erk activation and autophagy
(reduced intensity of the LC3II band) in the aortic SMCs (Fig-
ure 6L).We next investigated whether Erk activation was respon-
sible for the greater survival rate of the wild-type microglia and
vascular cells. We found that U0126 and A6355 (another Erk
inhibitor) treatment completely abolished the increased survival
rate of the wild-type microglia and vascular cells (Figures
6M–6O). Thus, our data demonstrated that Erk activation was
required for PUMA-induced autophagy and survival of vascular
and microglia cells.
PUMA Deficiency Decreased Vascular and Microglia
Cell Cytoplasmic Calcium Levels
It is known that in fibroblasts PUMA, but not Noxa, increases
cytosolic calcium levels (Shibue et al., 2006). Importantly, cyto-
plasmic calcium plays a critical role in inducing autophagy
(Høyer-Hansen et al., 2007; Swerdlow and Distelhorst, 2007)
and Erk activation (Agell et al., 2002; Schmitt et al., 2004). We
therefore studied whether PUMA affected intracellular calcium
levels in vascular and microglia cells. Using fluorescent Fluo-4
acetoxymethyl (Fluo-4AM) as an indicator of cytosolic calcium,
we found that Puma deficiency reduced cytosolic calcium levels
under a steady-state condition and upon ATP or mechanical
stimulation in primary retinal microglia (Figure 7A), primary
vascular ECs (Figure 7B), and primary vascular SMCs (Fig-
ure 7C). Consistently, Puma knockdown by RFP-Puma shRNA
decreased cytosolic calcium levels in primary retinal microglia
in the RFP-Puma shRNA expressing cells (Figure 7D, arrows in
the right panel). These data demonstrated that PUMA plays a(G andH) Immunofluorescence staining showed that overexpression of PUMA in p
LC3+ dots (A, arrows), whereas Puma deficiency decreased autophagy in the pri
DAPI, diamidino-2-phenylindole fluorescent staining of nuclei.
(I and J) Western blot showed that U0126 (an Erk inhibitor) treatment inhibited Erk
endothelial cells (TR-iBRB, J) as demonstrated by the decreased intensity of the
(K) Immunofluorescence staining showed that while PUMA overexpression induce
panel, arrows), U0126 treatment abolished PUMA-induced autophagy as shown
(L) Western blot showed that U0126 treatment inhibited Erk activation and auto
decreased intensity of the 16 kDa LC3II band.
(M–O) MTT assay showed that U0126 and A6355 (another Erk inhibitor) treatment
ECs and SMCs.
Scale bars represent 10 mm (G, H, and K). Data are represented as mean ± SEM
Cell Recritical role in regulating cytosolic calcium levels, which is essen-
tial in modulating Erk activation and autophagy.
DISCUSSION
Our findings that PUMA is critically required for the survival and
proliferation of vascular and microglia cells and plays important
roles in angiogenesis are highly unexpected, given that PUMA
has been considered as an essential apoptosis inducer for
more than 10 years (Yu and Zhang, 2008). We further revealed
that the survival/proliferative effect of PUMA was achieved by
induction of autophagy, a critical mechanism for cells to respond
to metabolic stress in order to survive, proliferate, and migrate
(Fan et al., 2010). Mechanistically, we revealed that PUMA plays
a critical role in regulating Erk activation and intracellular calcium
level. Our data thus revealed an unexpected function of PUMA
as a survival, proliferative, and angiogenic factor that contradicts
the known apoptosis-inducing role of PUMA.
Little was known about the function of PUMA in vascular and
microglia cells, even though the proapoptotic effect of PUMA
on other types of cells has been studied intensively. Indeed,
although Puma deficiency in mice decreased apoptosis in
fibroblasts and lymphocytes (Villunger et al., 2003), the same
apoptotic effect has not been observed on vascular or microglia
cells. In this study, we found that PUMA is abundantly expressed
in vascular andmicroglia cells. In vitro,Puma deficiency impaired
proliferation and survival of cultured vascular andmicroglia cells,
and nearly completely abolished the angiogenic response of
mouse aortic rings. In vivo, Puma deficiency by genetic deletion
or shRNA treatment decreased blood vessel and microglia
density in retina and brain, and suppressed angiogenesis in
different animal models. Consistently, Puma gene delivery
promoted cell proliferation and survival in vitro, and increased
blood vessel and microglia density in vivo. Interestingly, PUMA
was recently reported to be critically required for tumorigenesis
(Michalak et al., 2010), whereas other apoptotic genes, such as
p53 and Noxa, inhibited tumorigenesis (Michalak et al., 2010).
Although a different mechanism underlying the tumorigenic
activity of PUMA was suggested, it nevertheless indicated a
unique growth-promoting function of PUMA, at least under
certain conditions. In addition, while retinal microglia density
and angiogenesis were reduced in Puma-deficient mice, the
retinal astrocytes appeared to be normal, demonstrating a
cell-specific effect of PUMA. Indeed, other investigators have
also reported a cell-specific effect of PUMA (Qiu et al., 2008).rimary retinal microglia increased autophagy as demonstrated by the increased
mary brain endothelial cells as shown by the decreased LC3+ dots (B, arrows).
activation and PUMA-induced autophagy in primary microglia (I) and rat retinal
16 kDa LC3II band.
d autophagy in the TR-iBRB cells as shown by the increased LC3+ dots (middle
by the disappearance of the LC3+ dots (right panel).
phagy in aortic artery smooth muscle cells (SMCs) as demonstrated by the
abolished the greater survival rate of the wild-type (WT) microglia and vascular
; *p < 0.05, **p < 0.01. See also Figure S6.
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Figure 7. Critical Role of PUMA in Regu-
lating Cytosolic Calcium Levels of Microglia
and Vascular Cells
(A) Fluorescent Fluo-4 acetoxymethyl (Fluo-4AM,
green) was used as an indicator of cytosolic
calcium. Time-lapse microscopy showed that
PUMA deficiency decreased cytoplasm calcium
levels under a steady-state condition and upon
ATP stimulation in primary retinal microglia (n = 8,
p < 0.001).
(B) Time-lapse microscopy showed that PUMA
deficiency decreased cytoplasm calcium levels
under a steady-state condition and upon
mechanical stimulation in primary vascular endo-
thelial cells (n = 6, p < 0.01).
(C) Time-lapse microscopy showed that PUMA
deficiency decreased cytoplasm calcium levels
under a steady-state condition and upon
mechanical stimulation in primary vascular
smooth muscle cells (n = 8, p < 0.05).
(D) Puma knockdown by shRNA (RFP-Puma
shRNA) markedly decreased cytosolic calcium
levels in primary retinal microglia as demonstrated
by the diminished green fluorescence in the RFP-
Puma shRNA expressing cells (arrows in the right
panel).
(E) PUMA is required for the survival and prolifer-
ation of vascular and microglia cells by regulating
intracellular calcium level, Erk activation, and
autophagy, which is essential for cell survival,
proliferation and migration, particularly, under
conditions of metabolic stress.
Scale bars represent 20 mm. Data are represented
as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.Another important finding in this study is the critical role
of PUMA in inducing vascular and microglia cell autophagy
by regulating Erk activation and cytosolic calcium levels (Fig-
ure 7E). Autophagy is a homeostatic cellular recycling mecha-
nism essential for cell survival, proliferation, and migration
(Fan et al., 2010; Rabinowitz and White, 2010). It is especially
crucial when the cells are under metabolic stress, such as
hypoxia, even though uncontrolled autophagy can eventually
lead to cell death. Autophagy has been shown to be critically1282 Cell Reports 2, 1272–1285, November 29, 2012 ª2012 The Authorsrequired for macrophage migration and
T cell proliferation (Kadandale et al.,
2010). In this study, loss of PUMA by
gene deletion or shRNA markedly in-
hibited autophagy and impaired Erk acti-
vation in microglia, vascular ECs, and
SMCs, whereas Puma gene delivery
increased autophagy and Erk activation.
Calcium signaling plays a critical role in
Erk activation (Agell et al., 2002; Schmitt
et al., 2004) and autophagy induction
(Høyer-Hansen et al., 2007; Swerdlow
and Distelhorst, 2007). Because
shRNA-mediated loss of PUMA mark-
edly decreased cytosolic calcium levels
in microglia, the effect of PUMA on Erkactivation and autophagy may be mediated by its regulatory
effect on calcium signaling.
The previously unrecognized angiogenic effect of PUMA is
surprising, because no other BH3-only protein family member
has been shown to display such a function. It is reported that
microglia play crucial roles in angiogenesis, at least in part, by
producing potent angiogenic factors (Checchin et al., 2006; Liu
et al., 2005; Yamaguchi et al., 2011). In this study, we found
that the expression levels of many important angiogenic factors
were significantly reduced. Thus, apart from its direct effect on
vascular cells, PUMA plays an important role in angiogenesis
also by ensuring adequate microglia density and sufficient
amount of angiogenic factors.
Our finding that PUMA is a survival, proliferative, and angio-
genic factor may have important therapeutic implications.
Because of its potent apoptotic activity, PUMA has been consid-
ered as a promising therapeutic molecule for cancer treatment
(Ito et al., 2005). In addition, the therapeutic potential of tar-
geted PUMA inhibition to suppress apoptosis for the treatment
of degenerative diseases has attracted considerable research
interest (Yu and Zhang, 2008). However, our current findings
suggest that Puma gene delivery or inhibition may lead to unde-
sired effects on vascular and immune systems and warrant more
careful investigations.
Although we have demonstrated an unexpected function of
PUMA using comprehensive systems and approaches, out-
standing questions remain. For example, we currently cannot
explain how PUMA regulates cytosolic calcium levels and Erk
activation. Also, it remains elusive how the functional property
of PUMA is regulated to fulfill its autophagy or apoptotic activities
in different cells or under different conditions. It is possible that
there may be intermediate context-dependent molecules medi-
ating the different activities of PUMA. Moreover, although our
data demonstrated a cell-autonomous function of PUMA in
microglia and vascular cells, this does not rule out the possibility
that programed elimination of certain types of retinal cells (e.g.,
neurons) by PUMA during development might signal the pro-
liferation of retinal microglia and vascular cells. Future studies
are needed to answer these questions. In summary, our data
revealed an angiogenic activity of PUMA, which can act as a
survival and proliferative factor by modulating autophagy, and
demonstrated an unexpected complexity of PUMA function.
EXPERIMENTAL PROCEDURES
Animals, Intraocular Injections, and Tissues
The mice used and the eye tissue isolation are described in the Extended
Experimental Procedures. For Puma knockdown in vivo, 2 mg/0.5 ml/eye of
pLKO.1 DNA plasmid encoding the mouse Puma shRNA or the pLKO.1 empty
vector (Open Biosystems) together with the in vivo-jetPEI reagent (Polyplus-
transfection) was injected into P1 mouse vitreous according to the manu-
facturer’s instructions. For Puma gene delivery in vivo, 2 mg/0.5 ml/eye of
pCMV6-AC-RFP vector encodingmouse PUMAor the pCMV6-AC-RFP vector
without PUMA (OriGene Technologies) with the in vivo transfection reagent
was injected into P1mouse vitreous. In vivomicroglia depletion was described
previously (Checchin et al., 2006).
Immunofluorescent Staining and Retinal Image Analysis
Immunofluorescent staining and retinal image analysis are described in the
Extended Experimental Procedures. The reagents used for staining were: iso-
lectin GS-B4 (IB4, Invitrogen), DAPI (Invitrogen), rabbit anti-mouse CD11b (BD
PharMingen), rat anti-CD31 (PharMingen), rabbit anti-iba1 (Wako), rabbit anti-
PUMA (Cell Signaling), goat anti-mouse PDGFRa (R&D), mouse anti-GFAP
(Sigma-Aldrich), rabbit anti-LC3B (NovusBiologicals), and the Alexa Fluor fluo-
rescence-conjugated IgGs (Invitrogen).
Western Blot and Real-Time PCR
Western blot was performed as described (Tang et al., 2010). The antibodies
used were: rabbit anti-PUMA (Cell Signaling, Sigma-Aldrich), rabbit anti-
FGF2 (Santa Cruz), rat anti-IL6 (Biolegend), armenian hamster anti-CCL2 (Bio-Cell Relegend), rabbit anti-LC3B (Novus Biologicals), rabbit anti-M-CSFR (Cell
Signaling), mouse anti-p44/42 MAPK (Erk1/2) (Cell Signaling), and rabbit
anti-Phospho-p44/42MAPK (Erk1/2) (Cell Signaling). Monoclonal anti-b-actin-
peroxidase (Sigma-Aldrich) was used as an internal control. Real-time PCRs
were performed in triplicates as described (Tang et al., 2010) and repeated
at least once. Primers used are listed in Table S3.
Cornea Pocket and Aortic Ring Assays
The mouse cornea pocket assay was performed as described (Li et al., 2008;
Zhang et al., 2009). Human VEGF165 (PeproTech) of 160 ng/pellet/cornea was
used in the experiments. CD11b+ microglia density within the active angio-
genic area was assessed using an Imager Z1 microscope and AxioVision soft-
ware (Carl Zeiss). The aortic ring assay was performed as described (Kumar
et al., 2010) using human VEGF165 and FGF2 (100 ng/ml, R&D Systems).
Images of the aortic rings were taken on day 7 after implantation andmicroves-
sels analyzed as described (Kumar et al., 2010). CD11b+ cells were analyzed
by immunostaining.
Laser-Induced Choroidal Neovascularization Model
The CNVmodel was performed as described (Zhang et al., 2009). Eight to ten-
week-old mice were used for experiments. A total of 1 mg/eye of pLKO.1
mouse Puma shRNA plasmid or the control pLKO.1 plasmid without the
Puma shRNA (Open Biosystems) together with the transfection reagent in vivo-
jetPEI (Polyplus-transfection) was injected into the mouse vitreous according
to the manufacturer’s instructions. CNV area was analyzed 1 week after laser
treatment using IB4 staining. Microglia density was analyzed by immunofluo-
rescence staining using Iba1 as a marker.
Primary Cell Isolation and Cell Culture
Primarymouse retina and brainmicroglia cells, astrocyte, brain ECs, and aortic
artery SMCs were isolated and cultured as described (Matsubara et al., 2000;
Saijo et al., 2009; Seidel et al., 1991). Cells within ten passages were used for
experiment. The immortalized TR-iBRB and RGC5 were cultured as described
(Li et al., 2008). The HUVEC (Lonza) and RAW264.7 macrophage cells (ATCC)
were cultured according to the manufacturer’s instructions.
Intracellular Calcium Assay
The intracellular calcium assay was performed according to the manufac-
turer’s instructions (Invitrogen) and is described in the Extended Experimental
Procedures. The primary retinal microglia cells transfected with a pRFP-C-RS
vector encoding the mouse Puma shRNA or the pRFP-C-RS vector encoding
a noneffective 29-mer scrambled shRNA (OriGene Technologies) were used
for experiments 3 days after transfection.
Proliferation, Survival, and Cell Chemotaxis Assay
Several methods were used to assess cell proliferation and survival, including
an MTT assay, a DAPI-TUNEL staining method, a BrdU assay, a trypan blue
exclusion assay, and a LIVE/DEAD viability/cytotoxicity assay (Invitrogen).
Primary cells isolated from six to eight mice were pooled and cultured for
experiments. Serum-free medium was used for EC, SMC, and 293FT cell star-
vation. The Hank’s balanced salt solution (Invitrogen) was used for microglia
starvation. For the MTT assay, experiments were performed according to
the manufacturer’s protocol (Invitrogen). The Erk inhibitor A6355 and Mek
inhibitor U0126 (10 mMeach, Sigma) were used to block the Erk pathway using
0.1% DMSO (Sigma-Aldrich) as a control. A DAPI (Invitrogen) and a TUNEL
(Roche) stainingmethodwas used to count the number of viable and apoptotic
cells in 24 fields (450 mm 3 350 mm each) each assay and the mean value
calculated. Experiments were performed in triplicate under a normoxic or
hypoxic condition (1% oxygen) and repeated at least once, and representative
data presented. For the BrdU proliferation assay, cells were cultured in
complete medium and cell proliferation assessed using a cell proliferation
ELISA BrdU colorimetric kit according to the manufacturer’s protocol (Roche).
For cell survival assay, primary retinal microglia cells were treated with mito-
mycin C (Sigma, 50 mg/ml) in serum-free medium for 2 hr to inhibit cell prolif-
eration and then cultured in serum-free medium with repeated mitomycin C
treatment every 24 hr. After 3 days, the viable cells were counted using a trypan
blue exclusion method. The viable and dead cells were also stained andports 2, 1272–1285, November 29, 2012 ª2012 The Authors 1283
analyzed using a LIVE/DEAD viability/cytotoxicity assay kit (Invitrogen). The
pLKO.1 Puma shRNA plasmid and the control pLKO.1 plasmid without the
Puma shRNA (Open Biosystems), and the pCMV6 Puma gene expression
plasmid and the control pCMV6 plasmid without the Puma gene (OriGene
Technologies), were transfected into the cells using a SuperFect reagent (-
QIAGEN) according to the manufacturer’s protocol. Puromycin (Sigma) or
G418 (Sigma) was used for selection according to the manufacturer’s
protocol. Three biological repeats were performed for each experiment and
the mean value from the repeats is presented. Microglia chemotaxis assay
was performed as described (Ma et al., 2009) using the chemoattractants
ATP (50 mM, Sigma), CCL2 (100 ng/ml, R&D), and CCL3 (50 ng/ml, R&D).
Statistical Analysis
Two-tailed Student’s t test was used for statistical analysis. Difference was
considered statistically significant when p < 0.05. Results are represented as
mean ± SEM of the number of determinations.
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